HOXB13 G84E Explained: What a 592,158-Man Study Says About Your Real Prostate Cancer Risk

HOXB13 G84E Explained: What a 592,158-Man Study Says About Your Real Prostate Cancer Risk

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: HOXB13 G84E is a real prostate cancer risk gene, but it is not a verdict. A September 2025 study of 592,158 men found that carriers, men who inherit one changed copy, were diagnosed about three times as often as other men. Those men were not picked for family history, so that figure runs lower than the ones family studies produced. Their tumors also looked ordinary, with much the same Gleason scores and much the same rates of advanced disease. HOXB13 is not a DNA-repair gene. A PARP inhibitor is a drug that blocks a DNA-repair enzyme. So a G84E result does not qualify a man for the PARP inhibitor pair now approved for prostate cancer. The FDA approved that pair on 2023-06-20, and Health Canada on 2025-01-30. What the result argues for is an earlier and more careful talk about screening, not a different drug.

What you’ll learn

• What a risk of “three times as often” works out to in plain numbers, against a US baseline of about 13 in 100
• Why one federal source says carrier cancer “may be more aggressive” while the largest study says it is not
• Where US and Canadian screening advice splits, and which grade decides whether the test is covered
• What the Genetic Information Nondiscrimination Act does not protect, and how Canada’s law differs

HOXB13 is a transcription factor, not a DNA-repair gene

Almost every hereditary cancer gene a reader has heard of does one job. It repairs damaged DNA. BRCA1, BRCA2, ATM, CHEK2 and PALB2 all sit in that family.

HOXB13 does not. The National Center for Biotechnology Information lists it as Gene ID 10481, on chromosome band 17q21.32. It belongs to the homeobox gene family, and it makes a transcription factor, a protein that switches other genes on and off.

MedlinePlus Genetics, run by the National Library of Medicine, adds two useful details. The HOXB13 protein binds to set stretches of DNA and steers how other genes work. It also acts as a tumor suppressor, which is a brake on cell growth.

Picture a building site. A repair gene is the crew that fixes typos in the plans. A transcription factor is the foreman who picks which plans get opened.

The variant itself

Item	Value
Gene	HOXB13, Gene ID 10481, chromosome 17q21.32
Variant name	NM_006361.6(HOXB13):c.251G>A (p.Gly84Glu)
Common short form	G84E, database reference rs138213197
ClinVar record	VCV000128031, germline classification last evaluated 2026-02-03
ClinVar classification	Pathogenic/Likely pathogenic; association, multiple submitters, no conflicts
Listed traits	HOXB13-Related Cancer Predisposition; Prostate cancer, hereditary, 9

MedlinePlus reports that the changes tied to prostate cancer alter the MEIS interacting domains of the HOXB13 protein. Those domains are the parts that let the protein team up with its partner proteins.

G84E was first tied to prostate cancer in 2012. The work looked at families picked because cancer tracked with chromosome 17q21-22. All 18 affected men with usable DNA in the four families found carried it.

How it is passed down

G84E follows an autosomal dominant pattern. One altered copy, from either parent, is enough to raise risk. Each child of a carrier has a 50 percent chance of getting that copy.

Raised risk is not the same as certainty. MedlinePlus notes that these changes are germline, meaning they sit in every cell of the body and can pass to the next child. It also says plainly that inheriting one does not guarantee disease. Other genes, the world around a man and his daily habits all play a part.

Keep the repair-gene contrast in mind. It settles a treatment question later on. For the TALAPRO-2 trial behind the drug talazoparib, the Health Canada record names 12 repair genes. Those 12 are listed in the treatment section below. HOXB13 is not one of them.

A lab report is a document, not a diagnosis. A family doctor or a genetic counselor should read the real report against a real family history.

Section recap: HOXB13 makes a transcription factor that MedlinePlus calls a tumor suppressor, and G84E alters its MEIS interacting domains. It is passed on in an autosomal dominant pattern, and it is not a DNA-repair gene.

The honest risk number, and why older figures run higher

This is the section most readers came for, so the arithmetic belongs in the open.

The founding 2012 report drew its families from a study of clustered prostate cancer. Among 5,083 unrelated men of European descent with prostate cancer, 1.4 percent carried G84E. Among 1,401 men without cancer, 0.1 percent did. That is about a 20-fold gap. The change was also far more common in early, familial disease, at 3.1 percent, than in later disease with no family pattern, at 0.6 percent.

That design has a known catch, called ascertainment bias. The families were recruited because cancer already ran through them. Such families carry extra inherited risk, and often shared habits, on top of G84E. So their carriers are not average carriers.

Three ways the number has been measured

Study	Design	Headline risk figure
Ewing 2012, New England Journal of Medicine	Families selected for linkage to 17q21-22	Carrier rate 1.4% in cases vs 0.1% in controls, about 20-fold
Karlsson 2014, European Urology	Two Swedish population-based case-control samples, 5,003 cases and 4,693 controls	Odds ratio 3.4 (95% CI, 2.2-5.4) and 3.5 (95% CI, 2.4-5.2)
Crawford 2025, Journal of the National Comprehensive Cancer Network	592,158 men in the VA Million Veteran Program, not selected on family history	Hazard ratio 3.17 (95% CI, 2.90-3.46) for any prostate cancer

The range in brackets is the 95 percent confidence interval, the band the true value most likely sits in.

The 2025 study is the largest of the three. Among 592,158 men, 1,660, or 0.3 percent, carried one copy of G84E. The models gave a hazard ratio of 3.17 for any prostate cancer. A hazard ratio compares how often an event happens in two groups over the same span of time. So 3.17 means carriers were diagnosed about three times as often as other men.

The figure for cancer that had spread was 2.99 (95% CI, 2.32-3.84). For death from prostate cancer it was 2.63 (95% CI, 1.66-4.19). That last number follows from the higher count of cases, not from worse tumors. If more carriers are diagnosed and their tumors grade out the same, more carriers die of the disease.

In the biopsy subset of 36,321 men, an adjusted model gave an odds ratio of 2.60 (95% CI, 1.94-3.52). An odds ratio compares the odds of an event in two groups. It answers a slightly different question than a hazard ratio does, so the two are not the same measure.

Turning a multiplier into people

A multiplier on its own tells a reader almost nothing. It needs a baseline.

Federal cancer registry data put the US lifetime risk of a prostate cancer diagnosis at about 13.2 percent. The National Cancer Institute states the same idea as roughly 1 in 8. The median age at diagnosis is 68, and five-year relative survival is 98.2 percent.

So the starting point is about 13 men in 100. Published carrier estimates sit in a band above that:

• The Swedish population series put the risk by age 80 at 33 percent (95% CI, 23-46) in carriers. In other men it was 12 percent (95% CI, 11-13).
• A polygenic score adds up many common gene changes, each of which nudges risk a little. For carriers who also sat in the top quarter of a 33-variant polygenic score, that Swedish figure rose to 48 percent (95% CI, 36-64).
• The National Cancer Institute’s PDQ summary, short for Physician Data Query, puts overall risk with G84E at roughly 3 to 5 times average. Its pooled odds ratio is 4.07 (95% CI, 3.05-5.45).
• PDQ reports that same odds ratio rising to 10.11 (95% CI, 5.97-17.12) for disease found at age 55 or younger.
• Penetrance is the share of carriers who go on to get the disease. PDQ lists penetrance from 33 percent by age 80 in the Swedish work to about 60 percent.
• UK data put penetrance at 62 percent (95% CI, 47-76) by age 85.

Read that band honestly. At the low end, about 33 carriers in 100 are diagnosed by age 80. That leaves about 67 who are not. At the high end, about 60 in 100 are diagnosed by 80, and about 40 are not.

Both the population figures and the family figures are defensible. They simply describe different men. A carrier with three affected first-degree relatives is not the average carrier in a veterans study.

A urologist or a genetic counselor can weigh one family history against these published bands.

Section recap: The largest unselected study puts the multiplier near 3.17. Published lifetime figures for carriers run from about 33 percent by age 80 to about 60 percent. Against a US baseline near 13 in 100, that is a big rise and still far from a sure thing.

More cancer, but not clearly a worse cancer

This finding is the one most consumer pages skip. It is also the strongest reason not to panic.

In the same set of 592,158 men, carriers were diagnosed a little younger. Past that, their disease looked ordinary. Gleason scores were spread much as they were in other men. The Gleason score is the pathologist’s grade for how odd the tumor cells look. Rates of cancer that had already spread, and of cancer that stopped responding to hormone treatment, were also much the same. Doctors call that second state castration-resistant disease.

The study authors put it in one sentence. Carriers have “a moderately increased lifetime risk of PrCa,” and “the PrCa that develops is not more aggressive, although it may occur at younger ages”.

Where the sources disagree

That is not the only position on record, and this article will not pretend otherwise.

Source	Position on aggressiveness
MedlinePlus Genetics, National Library of Medicine	States that HOXB13-related prostate cancer may be more aggressive in affected men
Million Veteran Program analysis, 2025	Similar Gleason distribution and comparable castration-resistant metastatic rates
AUA/SUO Early Detection Guideline, amended 2026	Groups HOXB13 among genes that “need further study”

The urology guideline is worth reading closely here. Its text says BRCA2 has the strongest evidence, with the IMPACT study showing roughly an eight-fold rise in aggressive cancer. It then names ATM, MLH1, MSH2, MSH6, PMS2, HOXB13, NBS1 and CHEK2 as genes that need further study. That is the most candid statement on record of how thin the carrier evidence is.

The 2026 patient version of the National Comprehensive Cancer Network screening guideline points the same way by leaving HOXB13 out. It names BRCA1 and BRCA2 as inherited changes tied to earlier and more aggressive disease. It makes no such claim for any other gene.

The limits of the big study

The 2025 result carries its own caveats. The men all get care through the Veterans Health Administration, so they are not a random sample of North American men. The mix of ancestries is listed as a limit rather than a published figure. As a general matter, groups under regular care get tested more often, and more testing finds more cancer.

The practical shift is in the question itself. On current evidence, HOXB13 changes whether and when a diagnosis happens, not how bad the disease is once found. A urologist is the right person to read a real biopsy result against this literature.

Section recap: The largest study found no extra aggressiveness in carriers. An NIH page still says the cancer may be more aggressive, and the urology guideline calls the question unsettled. Carry that split into the appointment.

A consumer report is a screen; a clinical panel is the confirmation

Most readers arrive holding a direct-to-consumer report titled “Hereditary Prostate Cancer (HOXB13-Related).” It helps to know exactly what that document is.

The Food and Drug Administration cleared it through the 510(k) route under number K211499. A 510(k) clearance means the maker showed the test is much like a product already on the market. That is a lower bar than a full approval. The record lists 23andMe Inc. as applicant, received 2021-05-14, with a decision of “Substantially Equivalent” on 2022-01-06. It sits under product code QAZ and rule 21 CFR 866.6090, the Cancer Predisposition Risk Assessment System, as a class II device.

Two things follow. The report is a cleared, regulated product, so it should not be waved away. It is also a spot check on one known change, not a full read of the gene.

Ancestry changes what a result means

G84E is not spread evenly across populations, and that fact cuts both ways.

• PDQ states that G84E “appears to be restricted to White men, primarily of European descent”.
• The rate is 1.34 percent among European American prostate cancer cases, against 0.28 percent in controls.
• It reaches up to 6.25 percent in Finnish men whose cancer starts early.
• G84E turned up in 1.3 percent of Swedish population controls, and the haplotype pattern fits a Nordic founder mutation.
• Other ancestries carry other HOXB13 changes: G135E in Chinese men, G132E in Japanese men, and X285K only in men of West African ancestry.

So a “variant not detected” result carries different weight by ancestry. For a Black man in the US, a negative G84E test explains very little. Registry data show prostate cancer rates of 200.1 per 100,000 in non-Hispanic Black men against 122.2 in non-Hispanic White men. Death rates run 36.2 against 18.1 per 100,000. G84E is rare in men of African ancestry and does not explain that gap.

The clinical route

Consumer results are not used to change medical care until a clinical lab confirms them. In the US, labs that do that confirming work are typically certified under CLIA and accredited by CAP, and the test is normally ordered alongside counseling.

A consensus conference published in the Journal of Clinical Oncology set out who should be offered germline testing. It recommended testing for men whose cancer has spread, and for men whose family history points to hereditary prostate cancer. For cancer that has spread, it recommended large germline panels plus testing of the tumor itself. It also treats consent before the test, and a talk after the result, as part of the process.

Different documents list different gene sets for different jobs. The list that matters for treatment is the 12-gene repair set in the Health Canada record. A genetic counselor can explain which panel a given lab actually runs before the blood draw.

Section recap: The consumer HOXB13 report is a cleared single-variant test, decided 2022-01-06 under K211499, not a full read of the gene. A negative result means different things by ancestry, and a positive one is confirmed in a clinical lab before it changes care.

Screening in the US and Canada: age 40, age 55, MRI, and who pays

Here the guidelines genuinely disagree, and a false consensus would be the wrong answer.

Body	Position relevant to a G84E carrier
US Preventive Services Task Force, 2018	Grade C for ages 55-69: the decision to undergo periodic PSA screening should be an individual one. Grade D against screening at 70 and older. No separate carrier recommendation
AUA/SUO, 2023 amended 2026	Statement 5, Strong Recommendation, Evidence Grade B: offer screening beginning at age 40 to 45 for people at increased risk, including germline mutations
NCCN patient guideline, 2026	Screening generally begins at 45 at average risk, and at 40 for higher risk, which includes inherited genetic changes
NCI PDQ, revised 2025-05-09	Screening should begin at age 40 for individuals with germline pathogenic variants that increase prostate cancer risk, versus 45 to 75 at average risk
Philadelphia Prostate Cancer Consensus Conference	Screening from age 40 recommended for BRCA2 carriers, “with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers”
Canadian Task Force on Preventive Health Care, 2014	Recommends against PSA-based screening in every age band examined, with no carrier carve-out

Note the consensus wording. HOXB13 sits in the “consider” tier, not the “recommend” tier. That reflects moderate agreement among experts, not a mandate.

The US coverage problem

The Task Force grade is not just a clinical opinion. It also decides money.

Federal rule 45 CFR 147.130(a)(1)(i) requires plans to cover, with no cost sharing, services the Task Force rates A or B. PSA screening for men aged 55 to 69 carries a grade C. So there is no federal no-cost guarantee for a screening PSA, and coverage depends on the plan.

One note on currency. The 2018 statement is still the current Task Force position, and an update is under way. As of 2026-08-30 that update had reached the final research plan stage, with no draft or final replacement issued.

The Canadian picture

Canada’s national position is stricter than either US body. The Canadian Task Force on Preventive Health Care advises against PSA-based screening in every age band it looked at. The advice is strong against for men under 55 and for men 70 and over, and weak against for ages 55 to 69. It sets out no carve-out for men who carry a germline variant.

Canada runs no national prostate screening program. Public coverage of a screening PSA in a man with no symptoms is therefore a provincial matter, and it varies. In practice, a Canadian carrier’s route to a test usually runs through a doctor who orders it for a stated reason.

What the tests actually do

The urology guideline treats PSA as the first screening test, a strong recommendation on grade A evidence. For ages 50 to 69 it supports screening every two to four years. It also allows an MRI before a first biopsy, to pick up more of the higher-grade cancers, as a conditional recommendation on grade A evidence.

Imaging finds more, which is not automatically good. A UK screening trial published in April 2025 makes that tension concrete. Men in the top tenth of a 130-variant polygenic score were offered an MRI plus a transperineal biopsy. That kind of biopsy takes tissue through the skin rather than through the rectum. They were offered it whatever their PSA level. The counts cascade like this:

• Of 468 men who finished that pathway, 187, or 40.0 percent, had prostate cancer.
• Of those 187, 103 were at intermediate risk or higher and warranted treatment.
• Of those 103, 74, or 71.8 percent, would not have been found by the usual route of a high PSA plus a positive MRI.

Two cautions about that trial. It enrolled men on a score built from many common gene changes, not on HOXB13 or any single-gene result. Its group was mostly of European ancestry. A polygenic score is a separate axis of risk that stacks with a single variant rather than replacing it.

The harms belong in the same talk. The urology guideline sets out a clinical principle here. Patients must be told that a biopsy can find cancer with so little risk of death that watching it, not treating it, is right. A biopsy is also a procedure with its own risks, which a urologist should walk through beforehand. A urologist and a family doctor are the two people to build a schedule with.

Section recap: US bodies split between a grade C at ages 55 to 69 and an offer of screening from age 40 to 45 for germline carriers. Canada’s national task force advises against screening at every age. In the US the grade also decides whether the test is covered with no cost sharing.

Treatment: the PARP inhibitor approvals that probably do not apply

Anyone searching HOXB13 will run into PARP inhibitor headlines. Closing that gap saves misplaced hope. PARP is an enzyme that patches small nicks in one strand of DNA. A PARP inhibitor is a drug that blocks that patch job.

Regulator	Product	Date	Indication
FDA, NDA 211651 ORIG-1	Talazoparib (TALZENNA)	2018-10-16	Original new molecular entity approval
FDA, NDA 211651 SUPPL-10	Talazoparib plus enzalutamide	2023-06-20	Efficacy supplement
FDA, current label effective 2026-06-01	Talazoparib plus enzalutamide	In force	Homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer
Health Canada, control number 271537	Talazoparib plus enzalutamide	2025-01-30	Notice of Compliance issued for HRR gene-mutated mCRPC
Any regulator	HOXB13-directed therapy	None as of 2026-08-30	No approved product targets HOXB13

In that table, homologous recombination repair, shortened to HRR, is a different repair job. It mends a clean break across both strands of DNA, by copying the matching chromosome. A cancer cell that has lost HRR has to lean on PARP instead. That is why blocking PARP hits such a cell hardest, and why both approvals turn on HRR genes. Both records write the setting as HRR gene-mutated mCRPC, short for metastatic castration-resistant prostate cancer, meaning cancer that has spread and no longer answers to hormone treatment.

The Health Canada file took a detour. The supplement was filed on 2023-01-19. The agency issued a Notice of Deficiency in February 2024, then cleared the narrowed use on 2025-01-30.

The pivotal trial behind both decisions was TALAPRO-2. Progression-free survival there means how long men went without the cancer growing on a scan. Per the Health Canada summary, that hazard ratio was 0.447 (95% CI, 0.328-0.610) in men whose cancer carried a repair-gene fault. In men with a BRCA fault it was 0.203 (95% CI, 0.114-0.361). Without a BRCA fault it was 0.685 (95% CI, 0.462-1.017). A hazard ratio below 1 favors the drug arm.

Why this does not reach HOXB13

Who qualifies turns on whether a repair gene is faulty. The Health Canada record defines that fault in TALAPRO-2 using 12 genes:

• ATM, ATR, BRCA1, BRCA2
• CDK12, CHEK2, FANCA, MLH1
• MRE11A, NBN, PALB2, RAD51C

HOXB13 does not appear on that list.

The label language is just as specific. The current FDA label covers talazoparib with enzalutamide for adults whose prostate cancer has spread and no longer responds to hormone treatment. It also requires a mutation in one of those 12 repair genes. A G84E result alone does not meet that description.

That is not a permanent verdict for any one man. If a carrier is ever found to have cancer that has spread, tumor and germline repair-gene testing is done at that point. That step stands on its own merits. The consensus conference names BRCA2, BRCA1 and the mismatch-repair genes as the priority genes for choosing treatment in that setting.

What is left, then

As of 2026-08-30 no regulator has approved any therapy aimed at HOXB13. No retrieved guideline names a drug to prevent cancer in carriers, and none lists removing a healthy prostate as an option. Both the urology guideline and the NCCN patient guideline handle HOXB13 under screening, not treatment.

What is on offer is surveillance. That is less dramatic than a drug, and more useful at this stage. A urologist can spell out what a real surveillance schedule involves before a carrier signs up for it.

Section recap: The FDA approved talazoparib plus enzalutamide on 2023-06-20, and Health Canada issued a Notice of Compliance on 2025-01-30. Both cover prostate cancer with a repair-gene fault. HOXB13 is not one of the 12 repair genes, and no HOXB13-directed therapy is approved anywhere.

Your brother, your sons, and your daughters

Cascade testing means offering the same test to relatives once a variant is documented in a family. The arithmetic is simple. The conversation rarely is.

Each first-degree relative, meaning a full sibling, a child or a parent, has a 50 percent chance of carrying the same change. That follows from the autosomal dominant pattern described earlier.

Brothers are often tested first, since they are already in or near the age band where screening choices get made. Consensus guidance treats the testing of relatives as part of the same process as consent and counseling. A brother who tests negative for the known family variant can set that one variant aside. A family history of prostate cancer is a risk factor in its own right, apart from any gene result. So the US lifetime figure of about 13 in 100 is a floor for him, not his risk. His own screening plan is a conversation with his own doctor.

The daughter question

Readers often ask this one hesitantly, so here is the direct answer. Daughters and sisters can carry G84E, and they can pass it to their sons at the same 50 percent chance. A woman has no prostate, so her own prostate cancer risk is zero. She is still a real link in the chain.

Whether G84E raises the risk of any other cancer is an open question. The sources behind this article address prostate cancer, not other cancers. So nothing here supports changing a woman’s own cancer screening because of a G84E result. That is a topic for a genetic counselor, not for a change a reader makes alone.

Where to find help in the US and Canada

• In the US, the National Society of Genetic Counselors publishes a directory that can be used to find a certified counselor.
• In Canada, the Canadian Association of Genetic Counsellors publishes a similar directory of clinics.
• The Journal of Clinical Oncology framework backs shared models between clinicians and genetic providers, because genetic counselors are in short supply.
• That same framework treats consent before the test, the talk after the result, and the testing of relatives as one connected process.

Two questions are worth asking rather than assuming. Ask whether the counseling visit can be done by video, and how the plan covers it. Ask the original lab what it charges to test one known family variant.

Language helps more than instructions here. A workable opener is short and factual. A test found an inherited change that raises prostate cancer risk. The same test is open to relatives, and a genetic counselor can explain what it would mean for each person.

Section recap: Each first-degree relative has a 50 percent chance of carrying G84E, and brothers are often tested first. Female relatives can pass it on while carrying no prostate cancer risk themselves. Consensus guidance treats consent, the result talk and the testing of relatives as one process run with a genetic counselor.

Insurance, employment and the legal gaps

This is where US and Canadian readers diverge most, and where general-interest articles are most often wrong.

Question	United States	Canada
Health insurance	GINA Title I bars health insurers from using genetic information for eligibility, coverage, underwriting or premium decisions	The Genetic Non-Discrimination Act bars requiring a test or disclosure as a condition of a contract or service
Employment	GINA Title II bars use in hiring, firing, promotions, pay and job assignments, at employers with 15 or more employees	Same statutory prohibitions apply to goods, services and contracts
Life insurance	Not covered by GINA	Covered by the Act in law, with limited effect on application forms in practice
Disability insurance	Not covered by GINA	Covered by the same statutory prohibitions
Long-term care insurance	Not covered by GINA	Covered by the same statutory prohibitions
Enforcement style	Civil regulatory framework	Criminal law, with fines and possible imprisonment

The National Human Genome Research Institute states the US limit in its own words. GINA’s health insurance protections “do not cover long-term care insurance, life insurance, or disability insurance”. The same page notes that some states add cover in those lines.

The federal protections that do exist are broad on the health side. They cover private insurers, Medicare, Medicaid, the Federal Employees Health Benefits Program and the Veterans Health Administration, with limited cover under TRICARE.

State law can narrow the gap

Where a man lives matters, and Florida is the clearest example. Florida Statutes section 627.4301, as amended in 2020, reaches health insurers, life insurers and long-term care insurers. Absent a diagnosis of a related condition, they may not cancel, limit or deny coverage on the basis of genetic information. They may not set different premium rates on that basis either, or ask for genetic information for any insurance purpose.

Two limits on that statute deserve equal billing. It does not create a standalone protection for disability income insurance. It also does not stop a life or long-term care insurer from reading an applicant’s medical record. A diagnosis written there can still count, even if it came from a genetic test.

For a man in the middle of a term life application, the order of events matters. That is a question for a licensed insurance professional, and for a genetic counselor before testing rather than after.

Canada’s different machinery

Canada took a criminal-law route instead of an insurance-regulation route. The Genetic Non-Discrimination Act, S.C. 2017, c. 3, received royal assent on 2017-05-04. Section 3 bars anyone from requiring a genetic test as a condition of providing goods or services, or of entering into or keeping a contract. Section 4 applies the same bar to requiring that results be handed over.

The penalties are steep. On indictment, the maximum is a fine up to $1,000,000 and up to five years in prison. On summary conviction, it is a fine up to $300,000 and up to twelve months.

The law survived a constitutional challenge. In Reference re Genetic Non-Discrimination Act, 2020 SCC 17, the Supreme Court of Canada upheld the Act 5-4 on 2020-07-10. The majority held it valid under Parliament’s criminal law power. The dissent would have found it a matter of provincial jurisdiction over property and civil rights.

Practice has lagged the statute. A 2024 review in FACETS looked at 16 Canadian life insurance forms, covering close to half of the life insurers working in Quebec. Only four companies said outright that applicants should not send genetic test results. The authors concluded that the Act has changed life insurer underwriting practice only modestly.

The part that is not legal at all

The weight of a carrier result is rarely mostly financial. Worry about a diagnosis that may never come is common. Yearly surveillance turns an abstract risk into a standing appointment. Telling relatives is repetitive, and disclosure fatigue is real.

Consensus guidance builds counseling into the process for that reason, covering consent before the test and a talk after it. Counseling before a test is easier to arrange than counseling after a surprise, and a family doctor can start that referral.

Section recap: GINA covers health insurance, and jobs at firms with 15 or more workers. It does not reach life, disability or long-term care insurance. Canada’s Act is criminal law, upheld 5-4 in 2020, yet a 2024 review found most life insurance forms unchanged.

Frequently asked questions

Will I get prostate cancer if I carry G84E?

Not necessarily. The largest unselected study reported a hazard ratio of 3.17, against a US baseline lifetime risk of about 13 in 100. Direct lifetime estimates for carriers run from 33 percent by age 80 in Swedish data to about 60 percent in other series. Discuss the number for one family history with a urologist or genetic counselor.

Will my children inherit it?

Each child has a 50 percent chance of inheriting the variant, because it follows an autosomal dominant pattern. Sons who inherit it carry the raised risk. Daughters have no prostate and no prostate cancer risk. They can still pass the variant to their own sons at the same 50 percent chance. A genetic counselor can advise on when to offer testing to an adult child.

Will this affect my health or life insurance?

In the US, health insurance is protected. GINA Title I bars health insurers from using genetic information in eligibility, coverage, underwriting or premium decisions. Life, disability and long-term care insurance are not covered, though some states add protections. In Canada, the Genetic Non-Discrimination Act bars requiring a test or disclosure as a contract condition. A 2024 review still found most life insurance forms unchanged.

Can my employer find out?

GINA Title II bars employers with 15 or more workers from using genetic information in hiring, firing, promotions, pay and job assignments. In Canada, the federal statute bars requiring a genetic test, or the handing over of results, as a condition of a contract or service. Criminal penalties attach. Workplace questions belong with an employment lawyer, not a medical article.

Should I get a second opinion or confirm the result?

Confirmation in a clinical laboratory is standard before a consumer result changes care. The consumer report is a cleared single-variant test under 510(k) K211499, not a full read of the gene. Consensus guidance routes germline testing through consent, a clinical-grade test and a talk afterward. A board-certified genetic counselor can arrange that step.

Section recap: A G84E result raises risk without settling it. Each first-degree relative has a 50 percent chance of carrying it, and a consumer result is confirmed in a clinical lab before it changes care. GINA protects health insurance and jobs, but not life, disability or long-term care cover.

Summary

HOXB13 G84E is a genuine autosomal dominant prostate cancer risk variant, found in 2012 and concentrated in men of Northern European ancestry. The best measurement in an unselected population comes from 592,158 men, at a hazard ratio of 3.17. Published lifetime estimates for carriers start near 33 percent by age 80, against a US baseline near 13 percent.

Three points do most of the practical work.

• The largest study found no extra tumor aggressiveness. An NIH page and the urology guideline leave that question open.
• HOXB13 is not a DNA-repair gene. So a carrier result does not open the door to the PARP inhibitor pair approved in the US on 2023-06-20 and in Canada on 2025-01-30.
• US and Canadian screening advice genuinely conflict, and in the US the grade also decides coverage.

Nothing here resolves those conflicts, because the evidence does not. No step aimed at HOXB13 carriers has been shown to save lives. That is why every recommendation above ends at a named professional rather than an instruction. The next step is an appointment with a family doctor and a board-certified genetic counselor, carrying these questions and the actual lab report.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Crawford TB, Nelson T, Karunamuni R, et al. (2025). Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men. Journal of the National Comprehensive Cancer Network 23(10):e257055 (15 September 2025). DOI 10.6004/jnccn.2025.7055. PMID 40953603. https://pubmed.ncbi.nlm.nih.gov/40953603/
2. McHugh JK, Bancroft EK, Saunders E, et al.; BARCODE1 Steering Committee (2025). Assessment of a Polygenic Risk Score in Screening for Prostate Cancer. New England Journal of Medicine 392(14):1406-1417 (10 April 2025). DOI 10.1056/NEJMoa2407934. PMID 40214032. ClinicalTrials.gov NCT03857477. https://pubmed.ncbi.nlm.nih.gov/40214032/
3. Ewing CM, Ray AM, Lange EM, et al. (2012). Germline Mutations in HOXB13 and Prostate-Cancer Risk. New England Journal of Medicine 366(2):141-149 (12 January 2012). DOI 10.1056/NEJMoa1110000. PMID 22236224. PMCID PMC3779870. https://pubmed.ncbi.nlm.nih.gov/22236224/
4. Karlsson R, Aly M, Clements M, et al. (2014). A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. European Urology 65(1):169-176 (January 2014; Epub 20 July 2012). DOI 10.1016/j.eururo.2012.07.027. PMID 22841674. https://pubmed.ncbi.nlm.nih.gov/22841674/
5. National Cancer Institute, National Institutes of Health. Genetics of Prostate Cancer (PDQ), Health Professional Version, last revised 9 May 2025; and SEER Cancer Stat Facts: Prostate Cancer. Both retrieved 30 August 2026. https://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq and https://seer.cancer.gov/statfacts/html/prost.html
6. MedlinePlus Genetics, National Library of Medicine (NIH), HOXB13 gene; NCBI Gene, HOXB13 homeobox B13, Gene ID 10481; ClinVar VCV000128031, NM_006361.6(HOXB13):c.251G>A (p.Gly84Glu), germline classification last evaluated 3 February 2026. All retrieved 30 August 2026. https://medlineplus.gov/genetics/gene/hoxb13/ and https://www.ncbi.nlm.nih.gov/clinvar/variation/128031/
7. US Food and Drug Administration, Drugs@FDA record for TALZENNA (talazoparib) NDA 211651, including ORIG-1 approved 16 October 2018, SUPPL-10 approved 20 June 2023 and SUPPL-12 approved 6 February 2024, with the current prescribing information effective 1 June 2026; FDA 510(k) K211499, 23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related), decision 6 January 2022; and Health Canada Regulatory Decision Summary, control number 271537, Notice of Compliance issued 30 January 2025. All retrieved 30 August 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651 and https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1780595754514
8. National Human Genome Research Institute (NIH), Genetic Discrimination and the Genetic Information Nondiscrimination Act of 2008; 45 CFR 147.130, Coverage of preventive health services; Florida Statutes section 627.4301, Genetic information for insurance purposes, as amended by chapter 2020-159. All retrieved 30 August 2026. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination and https://www.ecfr.gov/current/title-45/section-147.130
9. Genetic Non-Discrimination Act, S.C. 2017, c. 3, Justice Laws Website, Department of Justice Canada; and Reference re Genetic Non-Discrimination Act, 2020 SCC 17 (docket 38478, judgment rendered 10 July 2020), Supreme Court of Canada. Both retrieved 30 August 2026. https://laws-lois.justice.gc.ca/eng/acts/G-2.5/ and https://www.scc-csc.ca/judgments-jugements/cb/2020/38478/
10. US Preventive Services Task Force (2018). Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319(18):1901-1913 (8 May 2018). DOI 10.1001/jama.2018.3710. PMID 29801017. Recommendation page and update status checked 30 August 2026. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
11. Wei JT, Barocas D, Carlsson S, et al.; American Urological Association / Society of Urologic Oncology. Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, Amended 2026). Unabridged guideline PDF retrieved 30 August 2026. https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guidelines
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection, Version 2.2026; and NCCN Guidelines for Patients: Prostate Cancer Screening, 2026. Retrieved 30 August 2026. https://www.nccn.org/patients/guidelines/content/PDF/prostate-screening-patient.pdf
13. Giri VN, Knudsen KE, Kelly WK, et al. (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology 38(24):2798-2811 (20 August 2020). DOI 10.1200/JCO.20.00046. PMID 32516092. https://pubmed.ncbi.nlm.nih.gov/32516092/
14. Bell N, Connor Gorber S, Shane A, et al.; Canadian Task Force on Preventive Health Care (2014). Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 186(16):1225-1234 (4 November 2014). DOI 10.1503/cmaj.140703. PMID 25349003. https://pubmed.ncbi.nlm.nih.gov/25349003/
15. Fernando A, Kondrup E, Cheung K, Uberoi D, Joly Y (2024). Still Using Genetic Data? A Comparative Review of Canadian Life Insurance Application Forms Before and After the GNDA. FACETS 9:1-10. DOI 10.1139/facets-2023-0101. https://doi.org/10.1139/facets-2023-0101

Last updated: 2026-08-30

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article aggregates 15 sources from peer-reviewed medical literature and public health agencies (tier 1=9 / tier 2=6), including NIH resources (MedlinePlus Genetics, NCBI Gene, ClinVar, NCI PDQ, SEER and NHGRI), the US Food and Drug Administration, Health Canada, the US Preventive Services Task Force, AUA/SUO and NCCN guidelines, Canadian federal statute and Supreme Court sources, and PubMed-indexed publications. Editorial lead: Yu Mizuno, a non-physician research editor.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada).

Related: Hereditary Cancer category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-hereditary-cancer/hoxb13-hereditary-prostate-cancer-japan-g84e-g132e